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Abstract NADPH oxidase (Nox)-derived reactive oxy-
gen species (ROS) are known to be involved in angiotensin
II-induced hypertension and endothelial dysfunction. Sev-
eral Nox isoforms are expressed in the vessel wall, among
which Nox2 is especially abundant in the endothelium.
Endothelial Nox2 levels rise during hypertension but little
is known about the cell-specific role of endothelial Nox2 in
vivo. To address this question, we generated transgenic
mice with endothelial-specific overexpression of Nox2
(Tg) and studied the effects on endothelial function and
blood pressure. Tg had an about twofold increase in
endothelial Nox2 levels which was accompanied by an
increase in p22phox levels but no change in levels of other
Nox isoforms or endothelial nitric oxide synthase (eNOS).
Basal NADPH oxidase activity, endothelial function and
blood pressure were unaltered in Tg compared to wild-type
littermates. Angiotensin II caused a greater increase in
ROS production in Tg compared to wild-type aorta and
attenuated acetylcholine-induced vasorelaxation. Both low
and high dose chronic angiotensin II infusion increased
telemetric ambulatory blood pressure more in Tg compared
to wild-type, but with different patterns of BP change and
aortic remodeling depending upon the dose of angiotensin II
dose. These results indicate that an increase in endothelial
Nox2 levels contributes to angiotensin II-induced endothe-
lial dysfunction, vascular remodeling and hypertension.
Keywords Endothelium  Vascular tone  NADPH
oxidase  Hypertension  Reactive oxygen species
Introduction
Increased production of reactive oxygen species (ROS) is
involved in the pathophysiology of cardiovascular diseases
such as hypertension, especially in the setting of increased
activation of the renin-angiotensin system [7, 14, 21].
Increased levels of vascular ROS may induce vascular
endothelial dysfunction through the superoxide-mediated
inactivation of endothelium-derived vasodilator nitric
oxide (NO) as well as modulate intracellular signaling
pathways that promote vascular remodeling [21]. Both
these mechanisms can contribute to the development of
angiotensin-dependent hypertension although redox-regu-
lated pathways in the kidneys and the central nervous
system are also important.
NADPH oxidase proteins are major sources of ROS [2,
4, 18]. All NADPH oxidases contain a core subunit, termed
Nox, which catalyzes the transfer of electrons from
NADPH to molecular O2 and leads to ROS generation.
Five Nox isoforms (Nox1–5) have been identified, which
form the basis of distinct NADPH oxidases and have
varying requirements for other protein subunits. Among
these isoforms, Nox5 is absent in rodents [2]. In the vas-
culature, Nox2 and Nox4 are expressed in the endothelium,
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whereas vascular smooth muscle cells (VSMC) contain
predominately Nox4 and Nox1 [2, 4]. Nox2 is also
expressed in adventitial fibroblasts and in human conduit
artery VSMC [2, 4]. There are significant biochemical
differences between Nox1, 2 and 4. Whilst each of the
three Noxs (i.e. Nox1, Nox2 and Nox4) forms a heterodi-
mer with a p22phox subunit, Nox1 and 2 require the
binding of additional regulatory subunits for their activa-
tion whereas Nox4 is constitutively active and does not
require other cytosolic subunits for its activity. Nox2
activation is induced by agonists such as angiotensin II,
which cause post-translational modifications of oxidase
regulatory subunits (p47phox, p67phox, p40phox and
Rac1) and their subsequent association with the Nox2-
p22phox heterodimer. The isoform-specific expression of
Noxs in the different cell types of the vessel wall and the
co-expression of more than one isoform in individual cell
types both suggest that the different isoforms may have
distinct roles. However, cell-specific roles of Nox isoforms
in vivo remain poorly understood.
It is well established that NADPH oxidases are involved
in the pathophysiology of angiotensin II-dependent
hypertension and endothelial dysfunction but the roles of
the different Nox isoforms is less clear [4, 7, 17, 27]. Nox1
knockout mice were reported to have a reduced basal blood
pressure and an attenuation of angiotensin II-induced
hypertension and endothelial dysfunction [11, 20], whereas
mice with VSMC-targeted overexpression of Nox1 had
vascular hypertrophy and an enhanced pressor response to
angiotensin II [8]. Transgenic mice with VSMC-specific
overexpression of Rac1 (which is required for both Nox1
and Nox2 activity) also showed enhanced angiotensin II-
induced hypertension [13]. Studies in tissues from human
patients with hypertension, diabetes, heart failure or aging
have correlated endothelial vasodilator dysfunction with
increased Nox2 expression and activity [9, 10]. Nox2
knockout mice show improved endothelial dysfunction in a
model of renovascular hypertension [17] but no change in
basal blood pressure [5] or the hypertensive response to
chronic angiotensin II infusion [16], nor to chronic acti-
vation of the renin-angiotensin system [28]. The above
studies suggest that VSMC Nox1 is important in angio-
tensin II-induced hypertension but the cell-specific roles of
Nox2 and, in particular, the contribution of endothelial
Nox2 remains unclear.
In this study, we generated transgenic mice with endo-
thelium-targeted overexpression of Nox2 and investigated
the effect on vascular function and angiotensin II-induced
hypertension. We report that increases in endothelial
levels of Nox2 in vivo contribute significantly to the
enhancement of angiotensin II-dependent hypertension,
vascular remodeling and endothelial dysfunction.
Methods
Transgenic mice and tissues
All animal procedures were conducted in accordance with
the Guidance on the Operation of the Animals (Scientific
Procedures) Act, 1986 (UK Home Office). Transgenic mice
with endothelial-targeted overexpression of Nox2 were
generated utilizing a tie 2 promoter/enhancer construct [26]
containing the full length human Nox2 cDNA sequence.
Fertilized oocytes from CBA/C57Bl6 mice were microin-
jected with the construct and founder progeny was identi-
fied by PCR analysis of genomic DNA. Two independent
transgenic lines were generated and backcrossed for [10
generations into a C57Bl6 background. Experiments were
conducted using heterozygous male mice and wild-type
littermate controls aged between 8 and 16 weeks. Aortic
tissues for immunoblotting or mRNA expression analyses
were snap frozen in liquid nitrogen and stored at -80C.
Endothelial denudation on aortic rings was performed
using a fine wire threaded into the lumen.
Surgical procedures
Telemeter transducers (PA-C10, Data Sciences Interna-
tional, St. Paul, MN) were implanted under 2.5% isoflurane
anesthesia. The transducer was positioned in the aortic arch
via the left carotid artery whilst the transmitter body was
placed in a subcutaneous pocket in the right flank. Data
were collected after a 7-day recovery period. Angiotensin
II or saline was administered via osmotic minipumps
(Model 1002, Alzet, Cupertino, CA) implanted subcuta-
neously under 2% isofurane.
Western blotting
Aortic samples were lysed using a polytron homogeniser in
Tris HCl (25 mM) buffer solution (pH 7.2) containing
EGTA (2 mM), EDTA (5 mM), NaF (30 mM), b-glycer-
ophosphate (40 mM), sodium pyrophosphate (20 mM),
sodium orthovandate (1 mM), phenylmethylsulfonyl-flur-
oide (1 mM), benzamidine (3 mM), pepstatin A (5 lM),
and leupeptin (10 lM). Protein content was determined
using a Biorad Bradford Protein assay (Biorad, UK). Pro-
teins were separated by SDS-PAGE and transferred onto
nitrocellulose membrane. The antibodies used were: Nox2,
eNOS (BD Transduction Laboratories, UK); p22phox (gift
from F.Wientjes, University College London, UK); phos-
pho- and pan-ERK (Cell Signalling, MA); nitrotyrosine
(Abcam); and actin (Sigma, UK). Immunoblots were
quantified by densitometry, using the actin level for
normalization.
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Real-time RT-PCR
RNA was isolated using an SV total RNA isolation kit
(Promega, UK). cDNA was synthesized using avian mye-
loblastosis virus reverse transcriptase (AMV; Promega,
UK) at 42C for 90 min. Relative gene expression was
quantified on an Applied Biosystems 7000 sequence
detection system (Applied Biosystems, UK) using SYBR
Green and the comparative Ct method, with GADPH levels
used for normalization. Forward and reverse primer
sequences were as follow (all 50–30):
GAPDH: CGTGCCGCCTGGAGAA, CCCTCAGATG
CCTGCTTCAC; b-actin: GTGAAAAGATGACCCAGA
TCA, TGGTACGACCAGAGGCATACAG; p22phox: TG
GACGTTTCACACAGTGGT, AAAGAGGAAAAAGGG
GTCCA; Nox1: CATCCAGTCTCCAAACATGACAG,
GCTACAGTGGCAATCACTCCAGTA; Nox2: ACTCCT
TGGGTCAGCACTGG, GTTCCTGTCCAGTTGTCTTCG;
Nox4: TGAACTACAGTGAAGATTTCCTTGAAC, GAC
ACCCGTCAGACCAGGAAT; p47phox: AGAGTCGCCA
GGGCACTCT, TCTTCGCCTGGCTGTCAGT; p67phox:
AAGCTGTTTGCCTGTGAGGT, CTTCATGTTGGTTGC
CAATG; Catalase: GCTGAGAAGCCTAAGAACGCAAT,
CCCTTCGCAGCCATGTG; SOD1: GGACCTCATTTTA
ATCCTCACTCTAAG, GGTCTCCAACATGCCTCTCTTC;
SOD2: CACACATTAACGCGCAGATCA, GGTGGCGTT
GAGATTGTTCA; SOD3: GGGATGGATCTAGAGCATT
AAGGA, ACACCTTAGTTAACCCAGAAATCTTTTC.
Immunohistochemistry and aortic morphology
Aortic sections for immunohistochemistry were frozen in
OCT solution and stored at -80C. Immunostaining was
performed on 10 lm cryosections. Sections were incubated
with polyclonal anti-Nox2 (BD Transduction Laboratories)
and anti-CD31 (Chemicon) antibodies. Secondary anti-
bodies were conjugated to Alexafluor 488 or Cy3 and
analyses were performed on a Leica SP5 confocal micro-
scope (Leica, Germany). For aortic morphology, tissues
were pressure fixed in vivo with 0.9% saline perfusion
followed by 4% PFA and embedded in paraffin. 6-lm
sections were stained with hematoxylin and eosin. Digital
images were analyzed for aortic wall thickness using
Volocity software (Volocity v5.0, Perkin Elmer, USA),
measuring approximately 20 radial lines from the internal
elastic lamina to the external lamina per section [8].
Superoxide dismutase (SOD) activity
Aortic homogenates were prepared in extraction buffer
(NaPO4 10 mM, EDTA 5 mM, EGTA 5 mM, NaCl 50 mM,
Triton 1%, protease inhibitor cocktail 1% (Sigma), pH 7.8)
and separated by zymography on 12% non-denaturing
PAGE (Invitrogen, UK) in running buffer (Tris base
20 mM, glycine 150 mM, pH 8.5). The gel was subse-
quently soaked in the dark in potassium phosphate
(50 mM, pH 7.8) solution containing nitroblue tetrazolium
(NBT, 275 lg/ml), riboflavin (65 lg/ml) and N,N,N9,N9-
tetramethyl-ethylenediamine (Temedm 3.2 ll/ml). Bands
were developed by exposing the gel to light whilst washing
in dH2O. The SOD isoforms [SOD1, Cu/Zn-SOD; SOD2,
Mn-SOD; and SOD3, extracellular (ec)-SOD] were iden-
tified by their positions on the gel corresponding to their
relative molecular weights and subsequently quantified by
densitometry [6].
ROS measurements
NADPH oxidase activity was assessed by lucigenin-
enhanced chemiluminescence, as described previously
[12]. Briefly, fresh aortae were incubated with or without
angiotensin II (1 lM) for 30 min in DMEM at 37C, prior
to homogenization in a modified Krebs Henseleit solution
(NaCl 118 mM, KCl 4.7 mM, CaCl2 2.5 mM, NaHCO3
25 mM, KH2PO4 1.2 mM, MgSO4 1.2 mM, glucose
11 mM, HEPES 10 mM, pH 7.4) containing protease
inhibitor cocktail (0.05 ll/mg; Sigma). Tissue homoge-
nates (15 lg) were added to Krebs buffer solution, incu-
bated at 37C for 10 min, followed by addition of NADPH
(300 lM) and dark-adapted lucigenin (5 lM). Chemilu-
minescence was then measured on a plate luminometer
(Lucy 1, Rosys Anthos, Wals, Austria) over a 20- to
30-min period. All samples were performed in triplicate
and the level of superoxide production was calculated from
average area under the curve. In some experiments, one of
the following inhibitors was pre-incubated with the cell
homogenate for 20 min prior to the addition of NADPH:
the flavoprotein inhibitor, diphenyleneiodonium (DPI,
10 lM); a NOS inhibitor, N-nitro-L-arginine methyl ester
hydrochloride (L-NAME, 100 lM); a mitochondrial elec-
tron transport chain inhibitor, rotenone (50 lM); a super-
oxide scavenger, tiron (10 mM); a putative NADPH
oxidase inhibitor, apocynin (10 lM); or a xanthine oxidase
inhibitor, allopurinol (100 lM).
Vascular tone
Segments of the descending thoracic aorta were suspended
in an organ bath containing Krebs buffer solution com-
prising (in mM) NaCl 118.2, KCl 4.69, MgSO47H2O 1.18,
KH2PO4 1.19, glucose 11.1, NaHCO3 25.0, CaCl26H2O
2.5 and indomethacin 0.003 mM, pH 7.4 at 37C, for iso-
metric tension measurements. Rings were exposed to
vasoconstrictors or vasodilators. For vasodilation studies,
rings were pre-constricted to 75% of the maximal con-
traction to phenylephrine prior to addition of acetycholine
Basic Res Cardiol (2011) 106:527–538 529
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or sodium nitroprusside. In some experiments, aortic rings
were incubated with angiotensin II (1 lM) for 30 min with
or without tiron (10 mM) prior to any other agents. In a
different set of experiments, a single dose of N-methyl-L-
arginine acetate salt, (L-NMMA, 100 lM) was added to
aortic rings pre-constricted to 30% of the maximal
response to phenylephrine.
Statistics
Data are expressed as mean ± SEM. Comparisons between
Tg and wild-type were made by unpaired Student’s t test
for two groups, one-way ANOVA with Bonferroni post-
hoc testing for more than two groups, or repeated measures
ANOVA as appropriate. Two-way ANOVA was used to
compare responses to treatments between Tg and wild-
type. The entire concentration–response curves were
compared by non-linear regression analysis followed by the
extra sum-of-squares F test. Statistical analyses were done
on GraphPad Prism (v4.03 for Windows, San Diego, CA).
P \ 0.05 was considered significant.
Results
Endothelial-specific overexpression of Nox2 in vivo
Two independent lines of endothelium-targeted Nox2-
overexpressing mice on a C57/Bl6 background were
generated. The lines were similar and data presented herein
are from line 1. Tg and WT mice were obtained in the
predicted Mendelian ratio and there were no differences in
gross morphology or in body and organ weights between
genotypes (Online Resource 1). The level of Nox2 protein
was significantly increased (twofold) in Tg aorta compared
to wild-type (Fig. 1a) and was similarly increased in Tg
line 2 (Online Resource 2A). Isolated cultured coronary
microvascular endothelial cells (CMEC) of Tg also had a
twofold increase in Nox2 levels compared to wild-type
CMEC (Fig. 1b). Mechanical denudation of the endothe-
lium from aortic segments reduced Nox2 proteins levels in
both Tg and wild-type groups and abolished the difference
between groups (Fig. 1c), indicating that the increase in
Nox2 derived from the endothelium. The endothelial-
specificity of Nox2 overexpression was further confirmed
by immunostaining sections of aorta, where an increase in
Nox2 that co-localized with an endothelial marker, CD31,
was observed in Tg (Fig. 2).
The effect of Nox2 overexpression on NADPH oxidase
activity was investigated in aortic homogenates. NADPH-
dependent superoxide production was similar in Tg com-
pared to wild-type littermates (Fig. 3a). However, after
acute exposure of aortae to angiotensin II (0.1 lM,
30 min), there was a significantly greater increase in
NADPH oxidase activity in Tg compared to wild-type
(85% cf. 34%; Fig. 3a). Diphenyleneiodonium (DPI,
10 lM), tiron (10 mM) and apocynin (10 lM) inhibited
the chemiluminescence signal in all experiments, whereas
L-NAME (100 lM), rotenone (2 lM) and allopurinol
(100 lM) had no effect (Online Resource 2), indicating
that NADPH oxidase was the likely source. To also assess
in vivo activation of Nox2, we studied aortic tissue from
mice that were infused with saline or angiotensin II
(1.1 mg/kg/day for 2 weeks). Aortic nitrotyrosine levels
were quantified as a readout of increased NO/ROS inter-
action resulting from increased superoxide generation.
Angiotensin II infusion increased nitrotyrosine levels in
both groups of mice but the levels were significantly higher
in the Tg group (Fig. 3b). These data are consistent with
the knowledge that Nox2 oxidase is normally quiescent and
requires agonist activation so that an increase in expression
level per se will not increase oxidase activity [1].
Fig. 1 Endothelial-specific Nox2 overexpression. Representative
western blots and mean data showing Nox2 protein level in a WT
and Tg aorta and b isolated coronary microvascular endothelial cells.
n = 6 aortae/group, n = 5 CMEC isolations/group, *P \ 0.05.
c Nox2 protein level in WT and Tg aorta with endothelium (endo)
intact (?) or removed (-), as assessed by western blot. n C 3 per
group, *P \ 0.05
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Effect of Nox2 overexpression on NADPH oxidase
subunits, eNOS and antioxidants
We investigated whether overexpression of Nox2 led to
changes in other proteins required for Nox2 activity. There
were no differences in mRNA levels of p22phox, p47phox
or p67phox between Tg and wild-type aorta (Fig. 3c).
Because it is reported that p22phox and Nox2 proteins
stabilize each other [2, 4, 18], we also measured the protein
levels of p22phox. Indeed, this was found to be increased
approximately threefold in the Tg group (Fig. 3d). Nox2
overexpression did not result in any changes in levels of
Nox4, the main other Nox isoform expressed in the endo-
thelium (Fig. 3c). Nox1 mRNA levels were below the level
of detection in both groups (data not shown). There was no
difference either in the mRNA levels of endothelial NO
Fig. 2 Immunostaining for
Nox2. Aortic sections stained
for Nox2 (green) and CD31
(red) as an endothelial marker.
The yellow colour in the merged
images in the bottom panels
denotes co-localization. Scale
bars 50 lm
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synthase (eNOS) between Tg and wild-type groups
(Fig. 3c) or in the eNOS protein levels (Online Resource
2C).
Since the effects of ROS generated by NADPH oxidase
may be influenced by ambient levels of antioxidant
enzymes, in particular superoxide dismutases (SODs) and
catalase, we also assessed these. There was a slight but
significant reduction in SOD1 mRNA levels in Tg com-
pared to wild-type but no difference in levels of SOD2,
SOD3 and catalase (Fig. 3e). However, SOD1 activity was
unaltered in Tg compared to wild-type as were SOD2 and
SOD3 activities (Fig. 3f). Taken together, these data indi-
cate that a modest overexpression of Nox2 which does not
alter basal NADPH oxidase activity does not induce sig-
nificant changes in antioxidant genes or eNOS. Antioxidant
levels were also assessed in aorta from mice that had been
infused with angiotensin II (1.1 mg/kg/day for 2 weeks).
Whereas angiotensin II infusion increased the expression of
SOD1, SOD2 and catalase, the levels remained similar
between wild-type and Tg groups (Online resource 3).
Effect of Nox2 overexpression on vascular tone
To determine the effect of increased endothelial Nox2
levels on vasomotor tone, we studied isolated aortic rings
from Tg and wild-type littermate mice. Constrictor
responses to potassium chloride (80 mM) and phenyleph-
rine were similar between groups (Fig. 4a, b). Endothe-
lium-dependent vasorelaxation to acetylcholine and
endothelial-independent relaxation to sodium nitroprusside
were both similar in wild-type and Tg groups (Fig. 4c, d).
To study vasorelaxation under conditions where Nox2 was
activated, aortic rings were stimulated with angiotensin II
(1 lM, 30 min) prior to the assessment of dilator respon-
ses. A small but significant decrease in the maximum
acetylcholine-induced relaxation was observed in angio-
tensin II-treated wild-type rings compared to saline control
when comparing the entire curve but there was no change
in EC50 (logEC50: -7.37 ± 0.08 vs. -7.46 ± 0.04 M,
respectively, P = ns; n = 10) (Fig. 4e). The angiotensin
II-treated Tg group showed a greater reduction in
Fig. 3 Changes in NADPH
oxidase activity, subunits and
antioxidants. a NADPH oxidase
activity in WT and Tg aortic
homogenates under basal
conditions (left) and after
angiotensin II (AngII 0.1 lM,
30 min) stimulation (right).
n [ 10; P \ 0.05.
b Nitrotyrosine levels in aorta
from Wt and Tg mice treated
with saline or angiotensin II
infusion. Representative blots
and mean data from three
experiments (*P \ 0.05).
c mRNA expression of
p22phox, p47phox, p67phox,
Nox4 and eNOS in aorta.
N = 6, P = NS. d Protein
expression of p22phox in aorta.
Representative blots at top and
mean data from three
experiments at bottom.
*P \ 0.05. e mRNA expression
of SOD isoforms and catalase in
aorta. n [ 6, *P \ 0.05. f SOD
activity by NBT zymography in
aortic homogenates. N = 6,
P = NS
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Fig. 4 Endothelial function in
isolated aortae from Tg and WT
mice. a Aortic contraction to a
single dose of KCl (80 mM).
N = 10. b Dose response curve
to phenylephrine (PE; 10-9 to
10-6 M). N = 10.
c Endothelial-dependent
relaxation to acetylcholine
(ACh). N = 10. d Relaxation to
sodium nitroprusside (SNP).
N = 10. e, f Relaxation to Ach
in the presence and absence of
AngII (0.1 lM, 30 min) in WT
and Tg aorta, respectively.
N = 10. *P \ 0.05 comparing
EC50 and Emax. g, h Relaxation
to SNP in WT and Tg,
respectively, in the presence and
absence of AngII (0.1 lM,
30 min). N = 10. i, j Relaxation
to ACh in WT and Tg aortae,
respectively, after co-incubation
with AngII (0.1 lM, 30 min)
and the superoxide scavenger,
tiron (10 mM). N = 3, P = NS
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acetylcholine-induced relaxation with a modest but
significant rightward shift of the EC50 (logEC50:
-7.19 ± 0.05 vs. -7.37 ± 0.05 M, respectively, *P\ 0.05;
n = 10) (Fig. 4f). Angiotensin II administration had no
effect on endothelial-independent relaxation to sodium
nitroprusside in either group (Fig. 4g, h). Pre-treatment
with the superoxide scavenger, tiron (10 mM) prior to
angiotensin II treatment prevented the angiotensin II-
induced attenuation of the acetylcholine relaxation in both
Wt and Tg aorta (Fig. 4i, j). The level of basal NO for-
mation was assessed by studying the response to the NOS
inhibitor, L-NMMA, in lightly pre-constricted aortic rings
(30% of phenylephrine maximum). The response in Wt and
Tg vessels was found to be similar (3.9 ± 0.7 vs.
3.4 ± 0.6 mN, respectively, P = ns; n = 3).
Effect of Nox2 overexpression on blood pressure
and the in vivo response to chronic angiotensin II
infusion
Ambulatory blood pressure was measured in Tg and wild-
type mice by telemetry. There was no difference in sys-
tolic, diastolic or mean blood pressure between groups at
baseline (Fig. 5a). To assess the response to angiotensin II,
mice were implanted with osmotic minipumps infusing
either angiotensin II or saline over a 2-week period. Saline
infusion did not cause any changes in blood pressure
(Fig. 5a). A low dose of angiotensin II (i.e. 0.3 mg/kg/day),
which normally has no effect on blood pressure in wild-
type mice caused significant increases in systolic, diastolic
and mean blood pressure in Tg mice but no change in wild-
type littermates (Fig. 4b). We also tested the effects of a
high dose of angiotensin II (1.1 mg/kg/day). This resulted
in similar rises in systolic and mean blood pressure in Tg
and wild-type mice but diastolic blood pressure increased
to a significantly greater extent in Tg compared with wild-
type (Fig. 5c).Heart rates (Fig. 5, lower panels) and
activity level (not shown) were similar in the Tg and wild-
type groups).
Aortic remodeling
To assess whether the vasculature of Tg and wild-type
mice had undergone angiotensin II-induced structural
remodeling, we quantified medial area in aortic sections
obtained from animals subjected to angiotensin II or
saline infusion. A similar increase in medial area was
found in Tg and wild-type mice subjected to low dose
angiotensin II infusion (0.3 mg/kg/day) (Fig. 6a). With
the higher dose infusion of angiotensin II (1.1 mg/kg/
day), however, aortic medial thickness was significantly
greater in Tg compared to wild-type (Fig. 6a). The mean
data for these experiments are shown in Fig. 6b. Finally,
we investigated the effect of Nox2 overexpression on the
activation of ERK1, which may be involved in angio-
tensin II-induced structural remodeling. The protein levels
of phospho-ERK were similar in unstimulated wild-type
and Tg aorta but in angiotensin II-treated aorta, the levels
of phospho-ERK were significantly greater in the Tg
group (Fig. 6c).
Discussion
In this study, we have investigated the effects of endo-
thelial-targeted in vivo overexpression of the Nox2 isoform
of NADPH oxidase on vascular function and angiotensin
II-induced hypertension. Our main findings were that: (1) a
modest twofold increase in levels of endothelial Nox2 had
no effect on basal NADPH oxidase activity, vascular
function or blood pressure in the absence of agonist
stimulation, consistent with the knowledge that this iso-
form is quiescent unless stimulated [1, 2, 4, 18]; (2) there
were no significant compensatory changes in mRNA levels
of Nox4, eNOS, or catalase or in SOD1-3 activity after
Nox2 overexpression; (3) exposure to angiotensin II
resulted in a significantly greater worsening of endothelial
vasodilator function in Tg mice compared to wild-type but
the magnitude of effect was very modest; (4) angiotensin
II-induced hypertension was potentiated in Tg mice after
chronic infusion of either a low (normally subpressor) dose
or a high dose of angiotensin II; and (5) chronic high dose
angiotensin II infusion caused greater vascular remodeling
in Tg mice compared to wild-type. Taken together, these
results suggest that an increase in endothelial levels of
Nox2 contributes significantly to hypertension in settings
where there is increased activation of the renin-angiotensin
system, an effect that may involve endothelial dysfunction
and/or vascular structural remodeling.
Angiotensin II is well known to play a major role in the
initiation and progression of hypertension as well as other
vascular diseases [21]. Whilst the signal transduction of
angiotensin II responses is complex, a large body of evi-
dence points to an important role of ROS generated by
NADPH oxidases [15, 18, 21, 24]. Chronically elevated
levels of angiotensin II increase NADPH oxidase activity
and superoxide production in all layers of the vessel wall
but the relative contribution of different Nox isoforms and
different cell types to the development of hypertension
remains incompletely defined. As mentioned earlier, stud-
ies in gene-modified mouse models support an important
role for VSMC Nox1 in angiotensin II-dependent hyper-
tension [8, 11, 13, 20]. Expression levels of Nox2 increase
upon angiotensin II stimulation in endothelial cells in vitro
[25] as well as in the endothelium in situ in blood vessels
[17] but the role of Nox2 in the endothelium—a major site
534 Basic Res Cardiol (2011) 106:527–538
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of expression of this isoform—in the development of
hypertension is unclear.
In the current study, we undertook a specific endo-
thelium-targeted overexpression of Nox2 using the
well-established tie 2 promoter construct [26]. Endothe-
lial-specificity of overexpression was confirmed by several
approaches including immunostaining and the quantifica-
tion of Nox2 levels in isolated endothelial cells and in aorta
with or without endothelium. The degree of Nox2
expression that was achieved in Tg mice was comparable
with the levels that have been reported in experimental
models of endothelial dysfunction or hypertension [8, 11],
suggesting that the data may be pathophysiologically rele-
vant. Importantly, the basal endothelial-specific increase
in Nox2 levels was not accompanied by potentially
confounding changes in levels of Nox4, antioxidant genes
or eNOS. Previous studies in which p22phox was overex-
pressed in VMSC in vivo were accompanied by numerous
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Fig. 5 Effect of chronic
angiotensin II treatment on
blood pressure in Tg and WT
mice. Ambulatory blood
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changes in antioxidant genes and eNOS which significantly
complicated interpretation of the effects observed [19]. A
previous study that generated an endothelium-specific
overexpression of Nox2 reported a basal increase in
NADPH oxidase activity which was accompanied by
increased levels of eNOS and SOD2 [3], which could
potentially confound the effects of the increased endothe-
lial Nox2 levels. In the current study, the lack of significant
change in antioxidant genes and eNOS may be related to
the fact that the increase in Nox2 overexpression was
relatively modest and that there was no basal change in
NADPH oxidase activity in the absence of agonist stimu-
lation (unlike the previous study [3]). Our results are in
agreement with data that Nox2 oxidase is normally quies-
cent and that ectopic increases in the expression of Nox2 in
defined cellular systems do not result in an increase in ROS
production in the absence of agonist stimulation [1, 2, 4,
18]. However, we also found that antioxidant gene
expression level remained similar between groups after in
vivo angiotensin II treatment. This suggests that factors
other than endothelial Nox2 (e.g. ROS generated from
other sources) may be more important for the regulation of
these genes. We found a significant increase in the protein
levels of the p22phox subunit, which binds to Nox2, in Tg
mice. This is most likely to be explained by the fact that the
stability of the two proteins increases when they are
complexed together [2, 4, 18], a postulate supported by the
finding that there was no change in mRNA levels of
p22phox. We also found no change in mRNA levels of the
cytosolic subunits p47phox and p67phox that are required
for Nox2 function.
Oxidase activity was significantly increased by angio-
tensin II stimulation in Tg aorta and this was accompanied
by a significant but rather modest worsening of endothe-
lium-dependent vasodilatation. The most likely explanation
for the modest impact of endothelial Nox2 on endothelial
function is that ROS generated in all layers of the vessel
wall during angiotensin II stimulation can interact with NO
so that the relative impact of endothelial Nox2-derived
ROS may be quite small. We also found significant dif-
ferences in angiotensin II-induced hypertension in vivo.
Using the gold-standard method of ambulatory telemetry,
we found that there was no difference in blood pressure
between Tg mice and wild-type littermates at baseline
(consistent with the lack of increase in basal NADPH
oxidase activity) but that a low dose chronic infusion of
angiotensin II that is subpressor in wild-type mice signifi-
cantly enhanced both diastolic and systolic blood pressures
in Tg mice. These findings are significant as they suggest
that a modest increase in endothelial Nox2 activity can lead
to significant hypertension. Whereas previous studies have
focused on VSMC Nox1 as being pivotal for the devel-
opment of AngII-induced hypertension [8, 11, 13, 20], the
current study suggests that endothelial Nox2 could also
contribute. Interestingly, at a higher dose of angiotensin II,
we found that only diastolic but not systolic pressure was
augmented in Tg mice. A previous study by Bendall et al.
[3] in a similar model of endothelial-specific Nox2 over-
expression also reported an increased systolic blood pres-
sure response to low dose angiotensin II infusion as
measured by tail-cuff plethysmography. However, that
study did not study the responses to high dose angiotensin
II nor were changes in diastolic blood pressure (which
cannot be accurately quantified by tail-cuff plethysmogra-
phy) reported. The difference between systolic and dia-
stolic blood pressure responses to high dose angiotensin II
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infusion could reflect a predominant effect of endothelial
Nox2 on resistance vessels, since it is known that resistance
vessel remodeling or increased tone can be an important
driver of diastolic hypertension. On the other hand, systolic
hypertension in this setting may be driven by mechanisms
independent of endothelial Nox2—such as other Noxs or
ROS-independent mechanisms [22, 23]. Several ROS-
dependent mechanisms can potentially contribute to the
development of angiotensin II-dependent hypertension.
Although the magnitude of difference in endothelium-
dependent relaxation between Tg and wild-type assessed in
aortic strips in vitro was quite modest, this could never-
theless be a contributor in vivo. The relevance of this
mechanism would ideally require the assessment of resis-
tance vessel tone and remodeling in vessels from animals
subjected to angiotensin II infusion. Although vessel tone
or NO production was not investigated in the mice treated
with angiotensin II infusion, we were able to demonstrate
evidence of enhanced NO/superoxide interaction in the
vessels of Tg animals—as assessed by nitrotyrosine levels.
We also assessed vascular structural remodeling in the
aorta and found that aortic medial area was greater after
high-dose but not low dose angiotensin II in the Tg mice.
A potential mechanism contributing to the increased
remodeling after high dose angiotensin II could be an
increased activation of ERK signaling after AngII infusion
in Tg mice compared to Wt. The lack of observed differ-
ence in aortic medial area in the low dose angiotensin II
group suggests that other mechanisms (such as altered
endothelial function) were important. It is also possible that
altered endothelial function in renal and/or central nervous
system vessels leads to perturbation of function that drives
hypertension [22, 23]. Additional studies will be required
to distinguish between these possibilities.
It is well documented that ROS generation and, in par-
ticular, NADPH oxidase are important components
involved in angiotensin II-induced hypertension [2, 4, 18,
21]. The recognition of differential expression of the
multiple Nox isoforms in the vessel wall, their varying
regulation, and their differential expression in disease set-
tings make it necessary to assess the contributions of
individual isoforms in different locations. The current
study shows that increases in endothelial Nox2 levels may
contribute significantly to the development of angiotensin
II-induced hypertension through mechanisms that may
include alterations in endothelial vasodilator function and/
or an enhancement of vascular structural remodeling.
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